H

Healthpeak Properties Inc
F:HC5

Watchlist Manager
Healthpeak Properties Inc
F:HC5
Watchlist
Price: 14.1 EUR Market Closed
Market Cap: 9.9B EUR

Healthpeak Properties Inc
Investor Relations

Healthpeak Properties Inc. stands as a testament to strategic healthcare real estate investing. Originally founded in 1985, this real estate investment trust (REIT) has intricately woven its operations into the fabric of the American healthcare landscape. With an astute focus on three primary segments—life science, medical office, and senior housing—Healthpeak has carved a niche as a powerhouse, aligning its portfolio with national healthcare trends. Life science assets often see collaborations with research institutions and biotech firms, while its medical office properties support outpatient services across the country. Within senior housing, Healthpeak addresses the growing demand from an aging population, choosing investments that reflect both demographic shifts and the evolution of senior care solutions.

The company’s revenue streams are as diversified as its portfolio, which notably reduces risk while maximizing revenue potential. As a REIT, Healthpeak primarily derives income from leasing space within its properties to healthcare operators and providers. This model benefits from stable, long-term lease agreements that often feature built-in rent escalators, providing predictable cash flows. Additionally, Healthpeak frequently engages in selective development and redevelopment initiatives, bolstered by its in-depth industry research. This strategy not only enhances the value of its existing assets but also positions the company to capture future growth opportunities. By leveraging these comprehensive strategies, Healthpeak Properties not only sustains its financial health but fortifies its position as a leader in healthcare real estate.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 24, 2025
AI Summary
Q3 2025

Performance: Q3 financial and operating results were in line with forecasts, supported by strong CCRC and outpatient medical performance.

Guidance: Management reaffirmed FFO and same-store guidance, while lowering interest expense and G&A guidance by $10 million due to better-than-expected cost control and debt pricing.

Portfolio Activity: The company is actively pursuing $1 billion or more in outpatient medical dispositions and recaps, with $200 million already under contract.

Lab Recovery: Life science leasing indicators are improving, with the pipeline doubling since Q1 and positive market sentiment driven by capital access, FDA progress, and biotech outperformance.

Technology & Efficiency: Internalized property management and AI/automation initiatives are delivering G&A savings and operational efficiency, with $90 million projected G&A for the year—less than five years ago despite portfolio growth.

Occupancy Outlook: Lab occupancy is expected to decline further into the high 70s percent before recovering, with new leasing and commencements offsetting some near-term headwinds.

Key Financials
FFO as Adjusted
$0.46 per share
AFFO
$0.42 per share
Same-Store Portfolio Growth (Year-to-Date)
3.8%
CCRC Cash NOI Growth (Quarter)
9.4%
CCRC Occupancy Sequential Change
Up 70 basis points
CCRC Occupancy Year-over-Year Change
Up 150 basis points
Outpatient Medical Leasing Volume (Quarter)
1.2 million square feet
Outpatient Medical Leasing Volume (Year-to-Date)
3.2 million square feet
Outpatient Medical Occupancy
91%
Outpatient Medical Cash Re-leasing Spread
5.4%
Outpatient Medical New Leasing (Quarter)
270,000 square feet
Outpatient Medical New Leases in October
123,000 square feet
Outpatient Medical Leases Under LOI
895,000 square feet
Lab Leasing Volume (Quarter)
339,000 square feet
Lab Leasing Volume (Year-to-Date)
1.1 million square feet
Lab Occupancy
81%
Lab Cash Re-leasing Spread (Renewals)
5%
Lab Lease Escalators
3% to 3.5%
Senior Unsecured Notes Issued
$500 million at 4.75%
Net Debt to Adjusted EBITDA
5.3x
Liquidity
$2.7 billion
Asset Sales and Loan Repayments (Year-to-Date)
$158 million
Dispositions Under Purchase and Sale Agreement
$204 million
Projected Annual G&A
$90 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Scott M. Brinker
President, CEO & Director
No Bio Available
Mr. Scott R. Bohn
Chief Development Officer & Head of Lab
No Bio Available
Mr. Adam G. Mabry
Chief Investment Officer
No Bio Available
Mr. Shawn G. Johnston
Executive VP & Chief Accounting Officer
No Bio Available
Mr. Andrew Johns CFA
Senior Vice President of Investor Relations
No Bio Available
Mr. Jeffrey H. Miller
General Counsel
No Bio Available
Ms. Lisa A. Alonso
Executive VP & Chief Human Resources Officer
No Bio Available
Mr. James A. Croy
Senior Vice President of Leasing - Outpatient Medical
No Bio Available
Mr. Antonio Acevedo
Senior Vice President of Asset Management - Outpatient Medical
No Bio Available
Mr. Jameson J. Bennett
Senior Vice President of Outpatient Medical Finance
No Bio Available

Contacts

Address
COLORADO
Denver
5050 South Syracuse Street, Suite 800
Contacts
+19494070700.0
www.healthpeak.com